They are a biopharmaceutical company leveraging their proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. They are initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. Their platform, which they refer to as DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. They believe there is a significant unmet medical need for convenient oral therapies in chronic immunological diseases that offer the therapeutic benefits of systemic biologics. They are leveraging their proprietary DELSCAPE platform to design and develop a pipeline of wholly-owned oral small molecule therapeutics against validated biologic targets to address chronic diseases in immunology and other therapeutic areas. In collaboration with Sanofi, they are also developing a therapeutic candidate for immuno-oncology indications.